Dr Reddy’s Lab launches Treprostinil Injection in the U.S.
Will be supplied as 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL or 200 mg/20 mL vials
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Dr Reddy’s Laboratories
Dr Reddy’s focuses on differentiated portfolio in key therapy areas for growth in India: GlobalData
DRL has earlier this month divested nine dermatology brands to Eris Lifesciences for Rs 2750 million ($33.3 million*). Within a…
Eris Lifesciences acquires nine dermatology brands from Dr Reddy’s for Rs 2,750 mn
Eris entered the dermatology segment through the acquisition of Oaknet Healthcare for Rs 6,500 million in May 2022 and…
Dr Reddy’s to acquire Mayne Pharma’s US generic prescription product portfolio
Dr Reddy's Laboratories has entered into a definitive agreement to acquire the US generic prescription product portfolio of…
LPC 150 Conclave to be held at NIPER Hyderabad on March 12, 2023
The theme of the event is Pharma 4.0: Digital transformation across pharmaceuticals
Dr Reddy’s Laboratories announces major recognitions in gender equality and sustainability
Included in Bloomberg Gender-Equality Index for sixth year in a row and S&P Global’s Sustainability Yearbook for the third…
Union Budget 2023: Industry lauds focus on R&D
Pharma leaders and experts share their views on Union Budget 2023 and give insights on the impact of the measures
Claims against Dr Reddy’s over Revlimid in US dismissed
On 22nd December, 2022 and 27th December, 2022, the plaintiffs voluntarily dismissed Dr Reddy’s Laboratories Limited and Dr…
Anti-trust litigation filed against Dr Reddy’s Laboratories and other generic pharma companies in US
The complaint seeks damages for purported overpayments and equitable relief
Indian drug 2DG can reduce heart damage by coronavirus, find US researchers
Their findings, based on research with fruit flies and mouse heart cells, were published in 'Communications Biology,' a 'Nature'…